

Please type a plus sign (+) inside this box → +

PTO/SB/08A (10-96)

Approved for use through 10/31/99. OMB 0654-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO <span style="float: right; font-size: 1.5em; font-family: cursive;">08/20/2003</span>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Complete if Known</b>	
Sheet	1	of	1
		Application Number	10/644,671
		Filing Date	Herewith
		First Name of Inventor	Coyle, Anthony J., et al.
		Group Art Unit	1644
		Examiner Name	J. OUSPENSKI
		Attorney Docket Number	MPI00-212CP1CN1M

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document (MM-DD-YYYY)	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			
JO	A1	5,521,288		Linsley et al.	05/28/1996	
	A2	5,881,310		Freeman et al.	01/19/1999	
	A3	5,942,607		Freeman et al.	08/24/1999	
	A4	5,968,510		Linsley et al.	10/19/1999	
	A5	US-2002/0095024	A1	Mikesell et al.	7-2002	
JO	A6	US-2002/0164600	A1	Freeman et al.	11-2002	

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document (MM-DD-YYYY)	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
	B1	WO	96/48815		Dana-Farber Cancer Institute	12/19/1996	All	
	B2	EP	1074617	A	Helix Res Inst	February 7, 2001		
	B3	WO	01/83750	A	Tseng et al.	November 8, 2001		
	B4	WO	01/94413	A	Squibb Bristol Myers	December 13, 2001		
	B5	WO	01/34629	A	Human Genome Sciences Inc	May 17, 2001		
	B6	WO	00/55375	A	Alphagene Inc	September 21, 2000		
	B7	WO	00/37643	A	Corixa Corp	June 29, 2000		
	B8	WO	01/49716	A	Corixa Corp	July 12, 2001		
	B9	WO	00/61612	A	Corixa Cor.	October 19, 2000		
	B10	WO	97/24447	A	Viagene Inc	July 10, 1997		
	B11	WO	95/05464	A	Arch Dev Corp	February 23, 1995		
	B12	WO	95/03408	A	Dana Farber Cancer Inst Inc	February 2, 1995		

Examiner Signature	Ilia Ouspenski	Date Considered	06/16/2006
--------------------	----------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation design number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Application Number	
		Filing Date	Herewith
		First Name of Inventor	Coyl, Anthony J., et al.
		Group Art Unit	
		Examiner Name	
Sheet 1 of 2	Attorney Docket Number	MPI00-212CP1CN1M	

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	C1	Database EMBL Sequence Database [Online] Hinxton, UK; 1 June 1999 (1999-06-01) S. Y. Tseng et al.: "Mus Musculus Butyrophilin-like (Btdc) mRNA, Complete cds." EMBL Sequence Accession No. AF142780	
IO	C2	Database EMBL Sequence Database [Online] Hinxton, UK; 22 February 2000 (2000-02-22) T. Isogai and T. Otsuki: "Homo Sapiens cDNA FLJ11010 fis, clone PLACE1003145; XP002193892. EMBL Sequence Accession No. AK001872	
	C3	Gerstmayer, et al., Cancer Immunology Immunotherapy 45(3-4): 156-158 (1997)	
	<del>C4</del>	<del>Schwartz, et al., Nat. Immunol. 3(5):427-434 (2002)</del>	
IO	C5	Inobe et al., J. Immunol. 157:582-588 (1996)	
	C6	ABBAS et al., Nature Medicine 5(12):1345-1346 (1999)	
	C7	DONG et al., Nature Medicine 5(12):1365-1369 (1999)	
	C8	FARGEAS et al., J. Exp. Med. 182:667-675 (1995)	
	C9	FREEMAN et al., The FASEB Journal 14(6):Abstract 153.34, Pg. A1170 (2000)	
	C10	HUTLOFF et al., Nature 397:263-266 (1999)	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation design number. <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Ilia Orespenzhi

06/16/2006

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Complete if Known</b>	
		Application Number	
		Filing Date	Herewith
		First Name of Inventor	Coyle, Anthony J., et al.
		Group Art Unit	
Sheet 2 of 2	Examiner Name		
	Attorney Docket Number	MPI00-212CP1CN1M	

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and-or country where published.	T <sup>2</sup>
	C11	LING et al., <i>J. Immunol.</i> 164(4):1653-1657 (2000)	
	C12	MAGES et al., <i>Eur. J. Immunol.</i> 30 (4) :1040-1047 (2000)	
IO	C13	PEACH et al., <i>Journal of Biological Chemistry</i> 270(36) :21181-21187 (1995)	
	C14	YOSHINAGA et al., <i>Nature</i> 402(6763):827-832 (1999)	

Examiner Signature	<i>Lion Oropelwski</i>	Date Considered	06/16/2006
--------------------	------------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation design number. <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.